Elevated pretreatment blood pressure and IV thrombolysis in stroke
暂无分享,去创建一个
P. Nederkoorn | R. V. van Oostenbrugge | D. Dippel | N. Kruyt | D. van de Beek | M. Dirks | T. Zonneveld
[1] Christopher S Coffey,et al. 2015 American Heart Association/American Stroke Association Focused Update of the 2013 Guidelines for the Early Management of Patients With Acute Ischemic Stroke Regarding Endovascular Treatment: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association , 2015, Stroke.
[2] M. Limburg,et al. Variation in Clinical Practice of Intravenous Thrombolysis in Stroke in the Netherlands , 2013, Cerebrovascular Diseases Extra.
[3] M. Wintermark,et al. Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association , 2013, Stroke.
[4] Peter Sandercock,et al. Risk Factors for Intracranial Hemorrhage in Acute Ischemic Stroke Patients Treated With Recombinant Tissue Plasminogen Activator: A Systematic Review and Meta-Analysis of 55 Studies , 2012, Stroke.
[5] C. Anderson,et al. Blood pressure lowering in acute phase of stroke: latest evidence and clinical implications , 2012, Therapeutic advances in chronic disease.
[6] Geoff Cohen,et al. The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial , 2012, The Lancet.
[7] W. Hacke,et al. Frequency of Increased Blood Pressure Levels During Systemic Thrombolysis and Risk of Intracerebral Hemorrhage , 2011, Stroke.
[8] Robbert Huijsman,et al. Promoting Thrombolysis in Acute Ischemic Stroke , 2011, Stroke.
[9] P. Nederkoorn,et al. Preventive Antibiotics in Stroke Study: Rationale and Protocol for a Randomised Trial , 2011, International journal of stroke : official journal of the International Stroke Society.
[10] W. Owens. Blood Pressure Control in Acute Cerebrovascular Disease , 2011, Journal of clinical hypertension.
[11] A. Alexandrov,et al. Pre–Tissue Plasminogen Activator Blood Pressure Levels and Risk of Symptomatic Intracerebral Hemorrhage , 2009, Stroke.
[12] M. Kaste,et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. , 2008, The New England journal of medicine.
[13] J. Grotta,et al. Aggressive blood pressure-lowering treatment before intravenous tissue plasminogen activator therapy in acute ischemic stroke. , 2008, Archives of neurology.
[14] Gary A. Ford,et al. Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. , 2008, Cerebrovascular diseases.
[15] A. Alexandrov,et al. Association of Pretreatment Blood Pressure With Tissue Plasminogen Activator-Induced Arterial Recanalization in Acute Ischemic Stroke , 2007, Stroke.
[16] Werner Hacke,et al. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study , 2007, The Lancet.
[17] Ching-Kuan Liu,et al. Eligibility for Recombinant Tissue Plasminogen Activator in Acute Ischemic Stroke , 2006, Cerebrovascular Diseases.
[18] Michael D. Hill,et al. Thrombolysis for acute ischemic stroke: results of the Canadian Alteplase for Stroke Effectiveness Study , 2005, Canadian Medical Association Journal.
[19] Joseph P Broderick,et al. Eligibility for Recombinant Tissue Plasminogen Activator in Acute Ischemic Stroke: A Population-Based Study , 2004, Stroke.
[20] J. Grotta,et al. Hypertension and its treatment in the NINDS rt-PA Stroke Trial. , 1998, Stroke.
[21] Joseph P. Broderick,et al. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. , 1995 .
[22] J. Broderick,et al. Factors Related to Intracranial Hematoma Formation in Patients Receiving Tissue‐Type Plasminogen Activator forAcute Ischemic Stroke , 1994, Stroke.
[23] J. Marler,et al. Urgent Therapy for Stroke: Part II. Pilot Study of Tissue Plasminogen Activator Administered 91-180 Minutes From Onset , 1992, Stroke.
[24] J. Broderick,et al. Urgent Therapy for Stroke: Part I. Pilot Study of Tissue Plasminogen Activator Administered Within 90 Minutes , 1992, Stroke.